恩度肝动脉灌注联合介入化疗栓塞治疗中晚期肝癌的临床观察

Objective:To study the efficacy and safety of hepatic arterial infusion of Endostatin(YH-16,Endostar),combined with transcatheter arterial chemoembolization(TACE) on advanced hepatocellular carcinoma.Methods:Thirty patients with advanced hepatocellular carcinoma were enrolled in the study.The patients received hepatic arterial infusion of Endostar combined with TACE.The efficacy was evaluated strictly after 1-2 cycles according to RECIST criteria and the value of AFP;quality of life(QOL) was evaluated according to Karnofsky scores.Adverse effects were evaluated too.Results:29 cases' efficacy was evaluated among the total 30 cases.The KPS were significantly increased after the treatment(80.39 ± 8.37 vs 73.93 ± 9.22,P = 0.002).Compared with control group,the objective response rate(CR and PR) and the rate of AFP negative changed were significantly higher(P = 0.021,P = 0.046).The adverse effects were not obvious.Conclusion:The QOL and preliminary efficiency of patients of advanced hepatocellular carcinoma may be improved by hepatic arterial infusion of Endostar combined with TACE,the rate of AFP negative changed were significantly higher too,and there are little of adverse effects.It is worthy to clinical generalization and further clinical observation.

Study of hepatic arterial infusion of Endostar combined with TACE on advanced hepatocellular carcinoma

Objective: To study the efficacy and safety of hepatic arterial infusion of Endostatin (YH-16, Endostar), combined with transcatheter arterial chemoembolization (TACE) on advanced hepatocellular carcinoma. Methods: Thirty patients with advanced hepatocellular carcinoma were enrolled in the study. The patients received hepatic arterial infusion of Endostar combined with TACE. The efficacy was evaluated strictly after 1-2 cycles according to RECIST criteria and the value of AFP; quality of life (QOL) was evaluated according to Karnofsky scores. Adverse effects were evaluated too. Results: 29 cases' efficacy was evaluated among the total 30 cases. The KPS were significantly increased after the treatment (80.39 ± 8.37 vs 73.93 ± 9.22, P = 0.002). Compared with control group, the objective response rate (CR and PR) and the rate of AFP negative changed were significantly higher (P = 0.021, P = 0.046). The adverse effects were not obvious. Conclusion: The QOL and preliminary efficiency of patients of advanced hepatocellular carcinoma may be improved by hepatic arterial infusion of Endostar combined with TACE, the rate of AFP negative changed were significantly higher too, and there are little of adverse effects. It is worthy to clinical generalization and further clinical observation.